Introduction
Breast implant-associated anaplastic large cell lymphoma (BI-ALCL), recently described as a distinctive form of CD30+ anaplastic large cell lymphoproliferation, was introduced as a new provisional T cell lymphoma entity in the 2017 WHO classification of hematological malignancies [1] . While the morphological and immunophenotypical features of BI-ALCL are indistinguishable from those of other ALK-negative ALCL, the specificity of BI-ALCL is its clinical presentation adjacent to a breast implant. Most cases confined to the periprosthetic effusion and capsule (seroma or Bin situ^lymphoma) have excellent outcomes, and a minority of patients present with a breast tumor mass, which is an adverse prognostic factor [2, 3] .
Yet, information on the genetic alterations associated with BI-ALCL is essentially limited to data derived from a few lymphoma specimens, all with seroma-associated presentation (summarized in Table 1 ) [4] [5] [6] [7] . Here, we report genetic findings in paired BI-ALCL samples of a patient whose disease presented as a solid tumor and recurred as an in situ capsular lesion.
Methods
Both specimens were routinely processed after formalin fixation and paraffin embedding in the Department of Pathology of the Institute Jules Bordet (Brussels, Belgium). Immunophenotyping was performed with routinely used antibodies on Ventana Benchmark/Ultra instruments. Immunohistochemistry for phospho-STAT3 (Tyr205) was performed with the D3A4 rabbit monoclonal antibody (Cell Signaling Technology, Danvers, MA, USA; ref. 9145), diluted at 1/100, and incubated overnight at 4°C after 3-min antigen retrieval in EDTA pH 9 in a pressure cooker.
Fluorescent in situ hybridization
Laboratory-developed FISH probes (Institute of Pathology, Lausanne) using bacterial artificial chromosome (BAC) combinations were used to explore rearrangements of DUSP22/ IRF4, TP63, and VAV1. For DUSP22/IRF4, break-apart probe consisted of telomeric RP3-416J7, labeled with Spectrum Orange, and centromeric RP11-615C17 and CTD-3139L20 labeled with Spectrum Green. For TP63, break-apart probe consisted of telomeric RP11-24F1, labeled with Spectrum Orange, and centromeric RP11-53D15 labeled with Spectrum Green. For VAV1, break-apart probe consisted of telomeric RP11-828J24, RP11-809P6, and RP11-134L9 labeled with Spectrum Green; and RP11-876D1, CTD-3131P, and RP11-1137G4 labeled with Spectrum Orange.
Targeted sequencing
DNA extracted from primary and recurrent FFPE tumor samples after enrichment by scraping under microscopic control was used to prepare DNA libraries with the KAPA HyperPlus library preparation kit (Roche). Target enrichment of the DNA libraries was performed by hybridization capture using a custom design of xGen® Lockdown® Probes (Integrated DNA Technologies) covering the full coding sequences of 26 genes recurrently mutated in various mature T cell neoplasms (ARID1A, ATM, BCOR, CARD11, CCR4, CD28, CTNNB1,  DDX3X, DNMT3A, FYN, IDH2, IRF4, JAK1, JAK3,  KMT2D , PIK3CD, PLCG1, PRKCB, RHOA, SETD2, 
Case report
The woman born in 1943 had elective bilateral insertion of silicone-filled breast implants (McGhan) in 1992 for cosmetic reasons. She presented in May 2011 with a right breast mass; MRI imaging showed a 3.9-cm solid lesion, no periprosthetic effusion, and enlarged right axillary lymph nodes. A PET-CT scan demonstrated a voluminous hypermetabolic lesion (SUV 13.3) in the lower right breast adjacent to the prosthesis and multiple slightly hypermetabolic lymph nodes in the right axilla (Fig. 1) . A tumorectomy was performed which comprised a 2.8-cm solid and partially necrotic infiltrating tumor made up of cohesive sheets of large anaplastic lymphoid cells (Fig. 2a, b) , abutting to the resection margin. By immunohistochemistry, the tumor cells were strongly positive for CD30, positive for CD8 and CD45 RO, and negative for ALK, EMA, CD2, CD3, CD4, CD5, CD7, CD15, CD20, CD45, and CD56, and had an activated cytotoxic phenotype (granzyme B+, perforin+) ( Fig. 2c-e) . A staging bone marrow biopsy was negative. The patient was treated with 5 cycles of CHOP (cyclophosphamide, daunorubicin, oncovin, prednisone) resulting in complete metabolic response. Consolidation with 2 cycles of high-dose methotrexate 3 g/ m 2 was subsequently administered, followed by autologous stem cell transplantation after BEAM conditioning in November 2011. In 2012, both prostheses were replaced by silicone-filled implants with biocell-textured shell (Allergan). In 2015, MRI demonstrated a rupture of the right prosthesis, and both prostheses were removed. The right periprosthetic capsule was macroscopically irregular and gritty and on histology showed a proliferation of large anaplastic cells confined to the surface and admixed with fibrin (Fig. 2f, g ). The immunophenotype was similar to that of the 2011 lesion, except for loss of CD8 expression and detectable EMA expression. An identical monoclonal rearrangement of TRG and TRB genes was demonstrated in both specimens. The patient did not receive further treatment and was last seen in July 2017, with no evidence of recurring disease.
The patient consented to further genetic analyses. FISH studies with break-apart probes for DUSP22/IRF4, TP63, and VAV1 loci showed no evidence of rearrangement (Fig. 2h, i) . We performed targeted deep sequencing analysis of both primary and recurrent tumors, using a panel of 26 genes relevant to T cell lymphoma oncogenesis. Two pathogenic hotspot mutations, one in the kinase domain of JAK1 (c.3290G>T (p.G1097V)) and the other in the SH2 domain of STAT3 (c.1840A>C (p.S614R)), were detected in both specimens. Moreover, an additional JAK1 truncating mutation (c.549dupT (p.D184*)) was detected in the first tumor only. Reflecting the presumed mutation-induced STAT3 activation, immunohistochemistry showed high levels of nuclear pSTAT3 expression in most tumor cells (Fig. 2j) .
Discussion
We report a patient with breast implants who developed BI-ALCL in the form of an unusual tumor mass presentation, was set to remission after surgical resection and systemic and intensive systemic treatment, and recurred 4 years later with a seroma-associated in situ capsular lesion in the same breast. The clinical management of the patient in 2011 was not in line with the current recommendations that would require upfront removal of the prosthetic implants, and indeed the delay for Both clonality studies and targeted deep sequencing results provided compelling evidence that the solid and seromaassociated lesions represented an identical clone, qualifying the second lesion as tumor recurrence. The tumor at presentation likely represents clonal evolution from a precursor lacking the second JAK1 mutation, and the recurrence evolved from the latter.
Very limited information is available in the literature regarding the genetic lesions underlying BI-ALCL (Table 1 ) [4] [5] [6] [7] . In total, karyotypes from three cell lines derived from BI-ALCLs and mutational analysis of seven primary tumor samples have been reported. The BI-ALCL-derived cell lines had markedly abnormal complex karyotypes with a neardiploid or a hypertriploid pattern) [4, 6] . In contrast, of the seven cases of BI-ALCL that were successfully analyzed by whole exome or targeted next-generation sequencing using a large panel of 465 cancer-associated genes, only four showed a small number of somatic variants, and three of the five cases successfully analyzed with a large cancer-oriented sequencing panel were wild-type for all tested genes [5, 7] . Strikingly, two of the four cases harbored a STAT3 S614R variant (as the sole abnormality in one case and in combination with pathogenic TP53 and SOCS1 mutations in the other), and another case harbored JAK1 (G1097V) somatic variant, indicating recurrent JAK/STAT mutations in BI-ALCL. The S614R variant of STAT3 is known as a gain-of function variant and has been found in a variety of T cell neoplasms including T-LGL leukemia, extranodal NK/T cell lymphoma, and systemic ALKnegative ALCL [8] . The JAK1 G1097V variant is also likely activating, since JAK1 mutants at the 1097 position reported a b c d e f g h i j Fig. 2 a, in other ALK-negative ALCLs have activating function [9] . Accordingly, functional studies on the BI-ALCL cell lines showed evidence of STAT3 activation, and the pharmacological inhibition of STAT3 induced in vitro cell death [6] . Our case was characterized by coexistent JAK1 G1097V and STAT3 S614R mutations. While mutation-induced activation of the JAK/STAT pathway constitutes a recurrent oncogenic mechanism in a variety of T cell malignancies [10] [11] [12] [13] [14] , the co-occurrence of dual JAK1/STAT3 mutations as observed in this BI-ALCL case represents a peculiar mutational pattern that yet has been reported only in a subset of nodal ALKnegative ALCLs [9] , suggesting that the pathogenic mechanisms operating in BI-ALCL overlap with those of systemic ALK-negative ALCLs. The significance of the additional JAK1 truncating mutation found in the first tumor only is uncertain: similar mutations in gynecological tumors might interfere with IFNγ-mediated mechanisms of immune surveillance [15] , but their impact on hematological neoplasias is unknown. Moreover, the same mutational pattern in the paired samples in this case indicates that the two types of clinical presentations of BI-ALCL (as a tumor or in association to a seroma) may not reflect molecularly distinct subtypes. Interestingly, including this case, the JAK1 G1097V and STAT3 S614R mutations were found in two and three BI-ALCL cases, respectively (Table 1) . Since numerous other hotspot mutations in these genes are found in other hemopathies [8] , despite the small number of BI-ALCL cases yet analyzed, it might be suggested that JAK1 G1097V and STAT3 S614R variants found by us and others could represent preferential recurrent drivers in this disease.
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